Through education, consensus building and advocacy, the Best Medicines Coalition addresses issues related to pharmaceutical regulatory review, assessment, reimbursement and supply Coalition positions are communicated to policy decision makers and stakeholders in a range of ways including through submissions to formal consultations, representation on advisory bodies, development and distribution of position documents, correspondence, meetings and presentations.
We support reforms which will allow all Canadians to access the medicines they need when needed, equitably and consistently, as outlined in our core positions and principles, and in formal submissions.
National Strategy for High-Cost Drugs for Rare Diseases:
BMC’s Submission to the National Strategy for High-Cost Drugs for Rare Diseases Online Engagement (March 26, 2021)
Pharmacare Advisory Council:
BMC’s Position Points on Key Recommendations
Joint Discussion Paper:
Better Pharmacare For Patients: Evaluating Policy Options (Français)
We support a strong regulatory framework for pharmaceutical pricing which ensures value and an environment which delivers the best possible care for patients.
Letter Responding to PMPRB Board Chair (June 8, 2021) (français)
We a support a national regulatory framework which protects Canadian patients, including addressing supply issues like drug shortages which put patients at risk.
Submission to the Government of Canada’s biomanufacturing consultation (March 2021)
We seek pharmaceutical assessment which incorporates patient-driven evidence and perspectives and leads to improved patient care.